Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study

Hurteau, Jean; Brady, Mark F.; Darcy, Kathleen M.; McGuire, William P.; Edmonds, Pamela; Pearl, Michael L.; Ivanov, Iouri; Tewari, Krishnansu S.; Mannel, Robert S.; Zanotti, Kristine; Benbrook, Doris M.

doi:10.1016/j.ygyno.2010.08.002

Cited by 68 publications

(46 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the best evaluated and most frequently used hormonal agents for the treatment of ovarian cancer are the selective ER modulator tamoxifen (Schwartz et al 1982, Hatch et al 1991, Ahlgren et al 1993, Johnson et al 1993, Scambia et al 1995, Bartlett et al 1996, Hofstra et al 1999, Benedetti Panici et al 2001, Hiscox et al 2004, Markman et al 2004, Hasan et al 2005, Wagner et al 2007, Hurteau et al 2010, Williams et al 2010, the selective ER antagonist fulvestrant (Argenta et al 2009), and the aromatase inhibitors letrozole (Papadimitriou et al 2004, Smyth et al 2007, Ramirez et al 2008) and anastrozole (del Carmen et al 2003, Krasner 2007. Other hormonal agents that have been evaluated in this context are progesterone receptor agonists (Ho 2003, Niwa et al 2008, Diep et al 2013 and antiandrogens, including flutamide and bicalutamide (Levine et al 2007).…”

Section: Endocrine Treatment Approachesmentioning

confidence: 99%

The role of reproductive hormones in epithelial ovarian carcinogenesis

Gharwan

Bunch

Annunziata

2015

Endocrine-Related Cancer

View full text Add to dashboard Cite

Epithelial ovarian cancer comprises w85% of all ovarian cancer cases. Despite acceptance regarding the influence of reproductive hormones on ovarian cancer risk and considerable advances in the understanding of epithelial ovarian carcinogenesis on a molecular level, complete understanding of the biologic processes underlying malignant transformation of ovarian surface epithelium is lacking. Various hypotheses have been proposed over the past several decades to explain the etiology of the disease. The role of reproductive hormones in epithelial ovarian carcinogenesis remains a key topic of research. Primary questions in the field of ovarian cancer biology center on its developmental cell of origin, the positive and negative effects of each class of hormones on ovarian cancer initiation and progression, and the role of the immune system in the ovarian cancer microenvironment. The development of the female reproductive tract is dictated by the hormonal milieu during embryogenesis. Intensive research efforts have revealed that ovarian cancer is a heterogenous disease that may develop from multiple extra-ovarian tissues, including both Mü llerian (fallopian tubes, endometrium) and non-Mü llerian structures (gastrointestinal tissue), contributing to its heterogeneity and distinct histologic subtypes. The mechanism underlying ovarian localization, however, remains unclear. Here, we discuss the role of reproductive hormones in influencing the immune system and tipping the balance against or in favor of developing ovarian cancer. We comment on animal models that are critical for experimentally validating existing hypotheses in key areas of endocrine research and useful for preclinical drug development. Finally, we address emerging therapeutic trends directed against ovarian cancer.

show abstract

Section: Endocrine Treatment Approachesmentioning

confidence: 99%

The role of reproductive hormones in epithelial ovarian carcinogenesis

Gharwan

Bunch

Annunziata

2015

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…GOG 198 compared tamoxifen and thalidomide in women with recurrent FIGO Stage III or IV epithelial ovarian, tubal, or peritoneal cancer who had completed first-line chemotherapy, and who subsequently had Gynecologic Cancer InterGroup (GCIG) documented CA125 progression. The study reported that women who received thalidomide had a 31% increased risk of disease progression (hazard ratio, 1.31), compared with those who were given tamoxifen [74]. The median progression-free survival was 3.2 months in the thalidomide group versus 4.5 months in the tamoxifen group.…”

Section: Follow-up For Malignant Epithelial Tumorsmentioning

confidence: 99%

Cancer of the ovary, fallopian tube, and peritoneum

Berek

Crum

Friedlander

2015

Intl J Gynecology & Obste

123

119

View full text Add to dashboard Cite

“…A randomized phase III trial of tamoxifen versus thalidomide (GOG#198) in EOC, fallopian tube or primary peritoneal cancer was reported in 2010 by Hurteau et al [57]. This trial sought to compare survival and toxicities of the two drugs in "biochemically recurrent" disease.…”

Section: -2000: Tamoxifen Trialsmentioning

confidence: 99%

“…Progressively rising CA125 is frequently the first sign of recurrent disease and precedes the development of clinical symptoms by a median of 3 months [58]. Within this trial, tamoxifen was used as the "reference" arm but proved more effective than thalidomide with only 3% of tamoxifen-treated patients experiencing grade 3 or 4 toxicities with improved overall survival and reduced risk of death [57].…”

Section: -2000: Tamoxifen Trialsmentioning

confidence: 99%

Endocrine therapy in epithelial ovarian cancer

Langdon

Gourley

Gabra

et al. 2016

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Introduction:The estrogen receptor (ER) is expressed at high levels in many epithelial ovarian cancers (EOC) and represents a potential target for endocrine therapy. Both anti-estrogens and aromatase inhibitors have been evaluated in phase II clinical trials. Areas covered:We present an overview of the phase II and phase III trials of anti-estrogens (tamoxifen and fulvestrant) and aromatase inhibitors (letrozole, anastrazole and exemestane) undertaken in epithelial ovarian cancer identified through a Pubmed search. We describe predictive biomarkers that are being investigated to identify responsive cancers. Expert commentary:The efficacy of endocrine therapy in epithelial ovarian cancer is likely to be confined to histological subtypes with the highest ER expression while low grade serous ovarian cancer appears to be one subgroup with good sensitivity to these agents. The low toxicity profile of these agents is favourable although their use is unlicensed and the optimal setting undefined. Prospective clinical trials of endocrine agents in the early relapse and maintenance settings are urgently required to establish their definitive role in the management of epithelial ovarian cancer

show abstract

Cited by 68 publications

References 34 publications

The role of reproductive hormones in epithelial ovarian carcinogenesis

The role of reproductive hormones in epithelial ovarian carcinogenesis

Cancer of the ovary, fallopian tube, and peritoneum

Endocrine therapy in epithelial ovarian cancer

Contact Info

Product

Resources

About